Rocuronium Hameln50 mg/5 ml

Rocuronium Hameln is a non-depolarizing neuromuscular blocking agent (skeletal muscle relaxant) with the following approved use:

Established / FDA-approved use

• Adjunct to general anesthesia — Rocuronium Hameln is used to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or to facilitate mechanical ventilation.

Rocuronium Hameln has no sedative, analgesic, or amnestic effect and must always be given together with adequate general anesthesia or sedation (see Precautions and Warnings). It is intended strictly for use in the operating room, intensive care unit, or other setting equipped for airway management, by personnel experienced in the use of neuromuscular blocking agents.

Rocuronium Bromide injection is supplied as a sterile, ready-to-use aqueous solution for intravenous use, commonly available in a strength of 10 mg/mL in single-dose or multiple-dose vials (e.g., 5 mL, 10 mL). Each vial contains Rocuronium Bromide as the active ingredient along with standard pharmaceutical excipients (e.g., sodium chloride, water for injection, and pH-adjusting agents).

Rocuronium Hameln is an intermediate-acting, non-depolarizing neuromuscular blocking agent of the aminosteroid class. It is administered intravenously during general anesthesia to produce skeletal muscle relaxation, most commonly to facilitate tracheal intubation, and to maintain muscle relaxation during surgical procedures or mechanical ventilation. Rocuronium Hameln has a comparatively rapid onset of action among non-depolarizing agents, which makes it useful when a fast onset is needed but a depolarizing agent such as succinylcholine is undesirable or contraindicated. Rocuronium Hameln does not affect consciousness, pain perception, or level of sedation.

Rocuronium Hameln belongs to the class of neuromuscular blocking agents, specifically the non-depolarizing (competitive) aminosteroid subclass of intermediate-duration skeletal muscle relaxants used in anesthesia.

Rocuronium Bromide acts as a competitive antagonist at nicotinic acetylcholine receptors on the motor end-plate of skeletal muscle, blocking the action of acetylcholine and preventing depolarization and muscle contraction. This produces flaccid skeletal muscle paralysis without affecting cardiac or smooth muscle at clinical doses, and without altering consciousness or pain sensation.

The ED95 (dose producing 95% depression of twitch response) of Rocuronium Bromide is approximately 0.3 mg/kg under balanced (opioid/nitrous oxide/oxygen) anesthesia. At an intubating dose of 0.6 mg/kg, onset of maximal block occurs in roughly 1 to 2 minutes, with clinically effective duration of approximately 30 to 40 minutes; higher doses used for rapid sequence intubation shorten onset time further. Recovery from 25% to 75% of control twitch height (recovery index) takes approximately 13 minutes. Rocuronium Bromide is metabolized to a limited extent by the liver and is eliminated primarily unchanged in bile and, to a lesser extent, urine; its neuromuscular blocking effect is reversed by acetylcholinesterase inhibitors (e.g., neostigmine) or by the selective relaxant-binding agent sugammadex.

Rocuronium Hameln is administered as a single intravenous bolus injection or, for maintenance, as a continuous intravenous infusion; it is not given intramuscularly, subcutaneously, orally, or by any route other than intravenous. It may be given undiluted for bolus dosing or diluted in a compatible solution (e.g., 0.9% sodium chloride, 5% dextrose, lactated Ringer's) for infusion. Rocuronium Hameln is chemically incompatible with alkaline solutions (e.g., propofol, barbiturates) in the same line; flush the line between administration of Rocuronium Hameln and any alkaline drug. It must be given only after the patient is unconscious/adequately anesthetized, with continuous monitoring of ventilation and neuromuscular function, and is intended solely for use by personnel trained in intubation and ventilatory support, in a setting equipped with resuscitation and reversal agents.

Several agents clinically alter the intensity or duration of neuromuscular blockade produced by Rocuronium Hameln:

Agents that may potentiate/prolong the effect of Rocuronium Hameln

• Volatile inhalational anesthetics (e.g., isoflurane, sevoflurane, enflurane) — potentiate and prolong neuromuscular blockade in a dose- and time-dependent manner.
• Certain antibiotics (aminoglycosides, vancomycin, tetracyclines, polymyxins) — can enhance neuromuscular blockade.
• Magnesium salts, lithium — enhance neuromuscular blockade.
• Local anesthetics, quinidine, procainamide — may potentiate blockade.

Agents that may reduce the effect of Rocuronium Hameln

• Chronic anticonvulsant therapy (e.g., carbamazepine, phenytoin) — associated with resistance to (a reduced effect of) Rocuronium Hameln, often requiring higher doses.

Reversal agents (pharmacodynamic interaction, used intentionally)

• Sugammadex and acetylcholinesterase inhibitors (e.g., neostigmine, edrophonium, typically with an anticholinergic) are used deliberately at the end of a procedure to reverse the neuromuscular blockade produced by Rocuronium Hameln.

Common

• Transient hypotension or hypertension (reported in roughly 2% of patients receiving Rocuronium Hameln)
• Tachycardia (reported more frequently in pediatric patients)

Less common

• Injection site reactions (pain, edema) or local irritation with extravasation
• Rash, pruritus
• Bronchospasm, wheezing
• Cardiac arrhythmia

Rare but serious

• Severe anaphylactic/anaphylactoid reactions, some fatal, have been reported with Rocuronium Hameln (see Contraindications and Precautions and Warnings).
• Prolonged or residual neuromuscular blockade with delayed recovery of muscle function and respiration.
• Malignant hyperthermia has been reported very rarely in association with general anesthesia that included Rocuronium Hameln, though animal data have not shown Rocuronium Hameln itself to trigger this reaction.

Pregnancy: There are no adequate and well-controlled studies of Rocuronium Hameln in pregnant women. Animal reproduction studies have not shown evidence of teratogenicity. Rocuronium Hameln should be used during pregnancy, including during cesarean delivery, only if the potential benefit justifies the potential risk to the fetus and only under the direction of a physician/anesthesiologist; it is not recommended for rapid sequence induction for cesarean section due to limited safety data in this specific setting.

Lactation: It is not known whether Rocuronium Hameln is excreted in human breast milk. Because Rocuronium Hameln is used only as a single or short-course intraoperative agent under direct medical supervision, and because it is not orally bioavailable, the risk to a breastfed infant is expected to be minimal; nonetheless, use during breastfeeding only if clearly needed and on the advice of a physician.

Facilities and personnel

Rocuronium Hameln should be administered only by, or under the supervision of, experienced clinicians familiar with its use, in a setting with immediately available facilities for tracheal intubation, mechanical ventilation, oxygen therapy, and an appropriate reversal/antagonist agent. Accidental administration of Rocuronium Hameln without adequate ventilatory support can cause respiratory arrest and death.

No effect on consciousness or pain

Rocuronium Hameln has no effect on consciousness, pain threshold, or awareness. It must always be given together with adequate anesthesia or sedation; Rocuronium Hameln must never be used as a substitute for anesthesia.

Anaphylaxis

Severe, potentially fatal anaphylactic reactions have been reported with Rocuronium Hameln; cross-reactivity with other neuromuscular blocking agents is possible in patients with prior sensitization.

Residual paralysis

Extubate only after adequate recovery of neuromuscular function has been confirmed, ideally with quantitative neuromuscular monitoring; residual paralysis increases the risk of postoperative respiratory complications. Elderly patients and those with hepatic, renal, or neuromuscular disease are at higher risk of prolonged blockade.

Prolonged ICU use

With prolonged continuous infusion in intensive care, tolerance and prolonged recovery can develop; continuous neuromuscular monitoring is essential, and myopathy has been reported with concurrent corticosteroid use.

Conditions altering dosing requirements

Use with caution and adjust dosing as needed in patients with hepatic or renal impairment (prolonged duration of action), obesity, burns, or neuromuscular disease (e.g., myasthenia gravis), and in patients with electrolyte imbalances (e.g., hypokalemia, hypermagnesemia) that affect neuromuscular transmission.

Malignant hyperthermia

Rocuronium Hameln has not been formally studied in patients susceptible to malignant hyperthermia; although animal data have not shown it to be a triggering agent, general anesthesia overall carries this risk and standard precautions should be followed.

Not for self-administration

Rocuronium Hameln is not a self-administered or ward-level medication; it is intended strictly for operating room, intensive care unit, or equivalent anesthesia settings.

Overdose or excessive dosing of Rocuronium Hameln produces prolonged neuromuscular blockade with extended skeletal muscle paralysis, including of the respiratory muscles, which can result in apnea and respiratory failure. This is a medical emergency requiring immediate attention: maintain a patent airway, provide controlled mechanical ventilation and adequate sedation until spontaneous recovery begins, and involve emergency/critical care support immediately. Once early spontaneous recovery is evident (confirmed with a peripheral nerve stimulator), an anticholinesterase agent (e.g., neostigmine) with an anticholinergic, or sugammadex, may be used under medical supervision to hasten reversal. Do not attempt to manage suspected overdose of Rocuronium Hameln outside of a monitored medical setting.

Store Rocuronium Hameln injection in a refrigerator (2°C to 8°C), protected from light, and do not freeze. If refrigeration is not available, unopened vials may generally be stored at room temperature (below 25°C) for a limited period as specified by the manufacturer's labeling on the vial/pack; once removed from refrigeration, do not return to the refrigerator. Keep out of reach of children and use only in a healthcare facility.

• Elderly: may have a prolonged duration of action with Rocuronium Hameln; individualize dosing and monitor neuromuscular function closely.
• Hepatic impairment: duration of action of Rocuronium Hameln may be prolonged; use conservative dosing (see Dosage and Administration).
• Renal impairment: onset generally unaffected but duration may be modestly prolonged; individualize dosing with monitoring.
• Obesity: dosing of Rocuronium Hameln should generally be based on ideal (lean) body weight to avoid overdosage and prolonged blockade.
• Burns / neuromuscular disease: such patients may show resistance or altered sensitivity to Rocuronium Hameln, requiring adjusted dosing under specialist supervision.
• Pediatric patients: see Pediatric Uses.
• Pregnancy and breastfeeding: see Pregnancy and Lactation.

Rocuronium Hameln is used only as needed for the duration of a surgical procedure or period of mechanical ventilation, either as single/intermittent intravenous doses or as a continuous infusion, and is not a chronic or take-home medication. The total duration and number of doses are determined by the anesthesiologist/intensivist based on the length of the procedure or ventilatory requirement and on neuromuscular monitoring.

Neuromuscular blocking agents; non-depolarizing (competitive), intermediate-duration, aminosteroid-class skeletal muscle relaxant used as an adjunct to general anesthesia.

Rocuronium Bromide competitively blocks nicotinic acetylcholine receptors at the motor end-plate of skeletal muscle, preventing acetylcholine from binding and triggering depolarization. This blocks neuromuscular transmission and produces flaccid skeletal muscle paralysis, which is antagonized (reversed) by acetylcholinesterase inhibitors such as neostigmine (which increase available acetylcholine) or by sugammadex (which selectively encapsulates and inactivates the Rocuronium Bromide molecule).

C

Rocuronium Hameln is used in pediatric patients for routine tracheal intubation and maintenance of muscle relaxation during surgery, with weight-based dosing generally similar to adult dosing for these purposes. However, Rocuronium Hameln is not recommended for rapid sequence intubation in pediatric patients because safety and effectiveness for that specific use have not been adequately established in this age group. Use in neonates and young infants requires particular caution and specialist (pediatric anesthesia) supervision, with continuous neuromuscular and cardiorespiratory monitoring, as QT interval prolongation has also been observed in pediatric patients receiving Rocuronium Hameln during anesthesia.